Jemal, A., Siegel, R., Xu, J. & Ward, E. Cancer statistics, 2010. CA Cancer J. Clin. 60, 277–300 (2010).
Di Lorenzo, G., Buonerba, C., Autorino, R., De Placido, S. & Sternberg, C. N. Castration-resistant prostate cancer: current and emerging treatment strategies. Drugs 70, 983–1000 (2010).
Kantoff, P. W. et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N. Engl. J. Med. 363, 411–422 (2010).
Drake, C. G. Prostate cancer as a model for tumour immunotherapy. Nat. Rev. Immunol. 10, 580–593 (2010).
Drake, C. G. Immunotherapy for prostate cancer: an emerging treatment modality. Urol. Clin. North Am. 37, 121–129 (2010).
Tagawa, S. T. et al. Anti-prostate-specific membrane antigen-based radioimmunotherapy for prostate cancer. Cancer 116, 1075–1083 (2010).
Whitmore, W. F. & Gittes, R. F. Studies on the prostate and testis as immunologically privileged sites. Cancer Treat. Rep. 61, 217–222 (1977).
Mercader, M. et al. T cell infiltration of the prostate induced by androgen withdrawal in patients with prostate cancer. Proc. Natl Acad. Sci. USA 98, 14565–14570 (2001).
Vesalainen, S., Lipponen, P., Talja, M. & Syrjänen, K. Histological grade, perineural infiltration, tumour-infiltrating lymphocytes and apoptosis as determinants of long-term prognosis in prostatic adenocarcinoma. Eur. J. Cancer 30, 1797–1803 (1994).
McArdle, P. A. et al. The relationship between T-lymphocyte subset infiltration and survival in patients with prostate cancer. Br. J. Cancer 91, 541–543 (2004).
Drake, C. G., Jaffee, E. & Pardoll, D. M. Mechanisms of immune evasion by tumors. Adv. Immunol. 90, 51–81 (2006).
Pound, C. R. et al. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 281, 1591–1597 (1999).
Sutherland, J. S. et al. Activation of thymic regeneration in mice and humans following androgen blockade. J. Immunol. 175, 2741–2753 (2005).
Sorrentino, C., Musiani, P., Pompa, P., Cipollone G. & Di Carlo, E. Androgen deprivation boosts prostatic infiltration of cytotoxic and regulatory T lymphocytes and has no effect on disease-free survival in prostate cancer patients. Clin. Cancer Res. 17, 1571–1581 (2010).
Tarassoff, C. P., Arlen, P. M. & Gulley, J. L. Therapeutic vaccines for prostate cancer. Oncologist 11, 451–462 (2006).
Higano, C. S. et al. Sipuleucel-T. Nat. Rev. Drug Discov. 9, 513–514 (2010).
Small, E. J. et al. Placebo-controlled phase III trial of immunologic therapy with Sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J. Clin. Oncol. 24, 3089–3094 (2006).
Sims, R. B. et al. Elevated eosinophils following treatment with Sipuleucel-T in men with prostate cancer is associated with antigen-specific immune response and prolonged survival [abstract 1491]. 52nd ASH Annual Meeting (2010).
Stewart, F. P. et al. Correlation between product parameters and overall survival in three trials of Sipuleucel-T, an autologous active cellular immunotherapy for the treatment of prostate cancer. J. Clin. Oncol. 28 (15 Suppl.), a4552 (2010).
Fuessel, S. et al. Vaccination of hormone-refractory prostate cancer patients with peptide cocktail-loaded dendritic cells: results of a phase I clinical trial. Prostate 66, 811–821 (2006).
Hildenbrand, B. et al. Immunotherapy of patients with hormone-refractory prostate carcinoma pre-treated with interferon-gamma and vaccinated with autologous PSA-peptide loaded dendritic cells—a pilot study. Prostate 67, 500–508 (2007).
Longo, DL. New therapies for castration-resistant prostate cancer. N. Engl. J. Med. 363, 479–481 (2010).
Nabhan, C. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N. Engl. J. Med. 363, 1966–1967 (2010).
Higano, C. S. et al. Phase 1/2 dose-escalation study of a GM-CSF-secreting, allogeneic, cellular immunotherapy for metastatic hormone-refractory prostate cancer. Cancer 113, 975–984 (2008).
Small, E. J. et al. Granulocyte macrophage colony-stimulating factor--secreting allogeneic cellular immunotherapy for hormone-refractory prostate cancer. Clin. Cancer Res. 13, 3883–3891 (2007).
Urba, W. J. et al. Treatment of biochemical recurrence of prostate cancer with granulocyte-macrophage colony-stimulating factor secreting, allogeneic, cellular immunotherapy. J. Urol. 180, 2011–2018 (2008).
Simons, J. W. et al. Phase I/II trial of an allogeneic cellular immunotherapy in hormone-naive prostate cancer. Clin. Cancer Res. 12, 3394–3401 (2006).
Small, E. et al. A phase III trial of GVAX immunotherapy for prostate cancer in combination with docetaxel versus docetaxel plus prednisone in symptomatic, castration-resistant prostate cancer (CRPC) [abstract 7]. Genitourinary Cancers Symp. (2009).
Brill, T. H. et al. Therapeutic vaccination with an interleukin-2-interferon-γ-secreting allogeneic tumor vaccine in patients with progressive castration-resistant prostate cancer: a phase I/II trial. Hum. Gene Ther. 20, 1641–1651 (2009).
Brill, T. H. et al. Allogeneic retrovirally transduced, IL-2- and IFN-γ-secreting cancer cell vaccine in patients with hormone refractory prostate cancer—a phase I clinical trial. J. Gene Med. 9, 547–560 (2007).
Berger, M., Kreutz, F. T., Horst, J. L., Baldi, A. C. & Koff, W. J. Phase I study with an autologous tumor cell vaccine for locally advanced or metastatic prostate cancer. J. Pharm. Pharm. Sci. 10, 144–152 (2007).
Higano, C. et al. A phase III trial of GVAX immunotherapy for prostate cancer versus docetaxel plus prednisone in asymptomatic, castration-resistant prostate cancer (CRPC) [abstract LBA150]. Genitourinary Cancers Symp. (2009).
Muir, G., Rajbabu, K., Callen, C. & Fabre, J. W. Preliminary evidence that the allogeneic response might trigger antitumour immunity in patients with advanced prostate cancer. BJU Int. 98, 989–995 (2006).
Kantoff, P. W. et al. Overall survival analysis of a phase II randomized controlled trial of a poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J. Clin. Oncol. 28, 1099–1105 (2010).
Dreicer, R. et al. MVA-MUC1-IL2 vaccine immunotherapy (TG4010) improves PSA doubling time in patients with prostate cancer with biochemical failure. Invest. New Drugs 27, 379–386 (2009).
Amato, R. J. et al. Vaccination of prostate cancer patients with modified vaccinia ankara delivering the tumor antigen 5T4 (TroVax): a phase 2 trial. J. Immunother. 31, 577–585 (2008).
Liu, M. A. Immunologic basis of vaccine vectors. Immunity 33, 504–515 (2010).
Hodge, J. W. et al. A triad of costimulatory molecules synergize to amplify T-cell activation. Cancer Res. 59, 5800–5807 (1999).
Arlen, P. M. et al. Clinical safety of a viral vector based prostate cancer vaccine strategy. J. Urol. 178, 1515–1520 (2007).
Gulley, J. L. et al. Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer. Cancer Immunol. Immunother. 59, 663–674 (2010).
Arlen, P. M. et al. A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer. Clin. Cancer Res. 12, 1260–1269 (2006).
DiPaola, R. S. et al. A phase II study of PROSTVAC-V (vaccinia)/TRICOM and PROSTVAC-F (fowlpox)/TRICOM with GM-CSF in patients with PSA progression after local therapy for prostate cancer: results of ECOG 9802 [abstract 108]. Genitourinary Cancers Symp. (2009).
Madan, R. A. et al. Analysis of overall survival in patients with nonmetastatic castration-resistant prostate cancer treated with vaccine, nilutamide, and combination therapy. Clin. Cancer Res. 14, 4526–4531 (2008).
Bilusic, M. et al. A randomized phase II study of flutamide with or without PSA-TRICOM in nonmetastatic castration-resistant prostate cancer (CRPC) [abstract 163]. Genitourinary Cancers Symp. (2011).
Rice, J., Ottensmeier, C. H. & Stevenson FK. DNA vaccines: precision tools for activating effective immunity against cancer. Nat. Rev. Cancer 8, 108–120 (2008).
McNeel, D. G. et al. Safety and immunological efficacy of a DNA vaccine encoding prostatic acid phosphatase in patients with stage D0 prostate cancer. J. Clin. Oncol. 27, 4047–4054 (2009).
Becker, J. T. et al. DNA vaccine encoding prostatic acid phosphatase (PAP) elicits long-term T-cell responses in patients with recurrent prostate cancer. J. Immunother. 33, 639–647 (2010).
Low, L. et al. DNA vaccination with electroporation induces increased antibody responses in patients with prostate cancer. Hum. Gene Ther. 20, 1269–1278 (2009).
Perambakam, S. et al. Induction of specific T cell immunity in patients with prostate cancer by vaccination with PSA146–154 peptide. Cancer Immunol. Immunother. 55, 1033–1042 (2006).
Slovin, S. F. et al. A polyvalent vaccine for high-risk prostate patients: “are more antigens better?”. Cancer Immunol. Immunother. 56, 1921–1930 (2007).
Noguchi, M. et al. Combination therapy of personalized peptide vaccination and low-dose estramustine phosphate for metastatic hormone refractory prostate cancer patients: an analysis of prognostic factors in the treatment. Oncol. Res. 16, 341–349 (2007).
Uemura, H. et al. Immunological evaluation of personalized peptide vaccination monotherapy in patients with castration-resistant prostate cancer. Cancer Sci. 101, 601–608 (2010).
Greenwald, R. J., Boussiotis, V. A., Lorsbach, R. B., Abbas, A. K. & Sharpe, A. H. CTLA-4 regulates induction of anergy in vivo. Immunity 14, 145–155 (2001).
Hodi, F. S. et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363, 711–723 (2010).
Fong, L. et al. Potentiating endogenous antitumor immunity to prostate cancer through combination immunotherapy with CTLA4 blockade and GM-CSF. Cancer Res. 69, 609–615 (2009).
Dieli, F. et al. Targeting human γδ T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer. Cancer Res. 67, 7450–7457 (2007).
Maniar, A. et al. Human γδ T lymphocytes induce robust NK cell-mediated antitumor cytotoxicity through CD137 engagement. Blood 116, 1726–1733 (2010).
Scher, H. I. et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J. Clin. Oncol. 26, 1148–1159 (2008).
Arlen, P. et al. The use of a rapid ELISPOT assay to analyze peptide-specific immune responses in carcinoma patients to peptide vs. recombinant poxvirus vaccines. Cancer Immunol. Immunother. 49, 517–529 (2000).
Hoos, A. et al. Improved endpoints for cancer immunotherapy trials. J. Natl Cancer Inst. 102, 1388–1397 (2010).
Hales, R. K. et al. Assessing oncologic benefit in clinical trials of immunotherapy agents. Ann. Oncol. 21, 1944–1951 (2010).